PATIENT RESOURCES
This website and specific webpage is intended for UK healthcare professionals only. The below resources are intended to support patients who have been prescribed Vocabria & Rekambys.
Patient Support Video
This video provides your patients with key information about their VOCABRIA + REKAMBYS treatment journey and the important role they play in their treatment success.
This comprehensive brochure provides your patients with key information about their VOCABRIA + REKAMBYS treatment journey and the important role they play in their treatment success.
REKAMBYS (rilpivirine long-acting injection), including the trademark, is owned by the Janssen Pharmaceutical Companies and used under license by the ViiV Healthcare group of companies. All other trademarks are owned by the ViiV Healthcare group.
PM-GB-CBR-WCNT-230010 | December 2023
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221441.
If you are from outside the UK, you can report adverse events to GSK/ViiV by selecting your region and market, here.
